JNJ-7777120 NEW
| Price | $64 | $97 | $173 |
| Package | 5mg | 10mg | 25mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2025-05-20 |
Product Details
| Product Name: JNJ-7777120 | CAS No.: 459168-41-3 |
| Purity: 99.83% | Supply Ability: 10g |
| Release date: 2025/05/20 |
Product Introduction
Bioactivity
| Name | JNJ-7777120 |
| Description | JNJ-7777120 is the first potent and selective non-imidazole histamine H4 receptor antagonist with Ki of 4.5 nM, exhibits >1000-fold selectivity over the other histamin receptors. |
| In vitro | JNJ 7777120 administration in mice inhibits the migration of tracheal mast cells from connective to epithelial tissues induced by histamine. Furthermore, JNJ 7777120 treatment in mice-derived bone marrow mast cells suppresses histamine-induced chemotaxis and calcium influx. In a peritonitis model induced by yeast polysaccharides in mice, JNJ 7777120 markedly inhibits neutrophil infiltration. The compound demonstrates oral bioavailability, with a 30% rate in rats and 100% in dogs, and a half-life of 3 hours for both species. |
| In vivo | JNJ 7777120 is an effective, selective antagonist for the H4 receptor, with little to no affinity for over 50 other targets. It binds with high affinity to the H4 receptor, exhibiting over a thousand times greater selectivity compared to other histamine receptors. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 40 mg/mL (144.01 mM), Sonication is recommended. |
| Keywords | JNJ-7777120 | JNJ 7777120 | Inhibitor | inhibit | HistamineReceptor | Histamine Receptor | H4 receptor |
| Inhibitors Related | Chlorphenesin | Histamine dihydrochloride | Meclizine dihydrochloride | Mirtazapine | Lidocaine | Famotidine | Mebhydrolin napadisylate | Sodium butanoate | Amitriptyline hydrochloride | Alginic acid | Trazodone hydrochloride | Mianserin hydrochloride |
| Related Compound Libraries | Highly Selective Inhibitor Library | Target-Focused Phenotypic Screening Library | Pain-Related Compound Library | Anti-Neurodegenerative Disease Compound Library | Bioactive Compound Library | Membrane Protein-targeted Compound Library | Inhibitor Library | NO PAINS Compound Library | Immunology/Inflammation Compound Library | Bioactive Compounds Library Max | Preclinical Compound Library | GPCR Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $0.00/1gram |
VIP1Y
|
Xi an Biohorlden Industry Trade Co Ltd
|
2025-04-14 | |
| $0.00/1kg |
VIP3Y
|
Henan Aochuang Chemical Co.,Ltd.
|
2022-09-26 | |
| $1.00/1g |
Apeloa production Co.,Limited
|
2024-06-19 | ||
| $1.00/1KG |
VIP8Y
|
Career Henan Chemical Co
|
2019-08-31 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, MA
INQUIRY